AGIO Stock Forecast: Agios Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 10 Wall Street analysts covering Agios Pharmaceuticals, Inc. hold a median 12-month price target of $43 — +55.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 87 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Agios Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (97): Sales and profits are climbing, and climbing faster than before.
Momentum (52): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
AGIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AGIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +55.9% from it.
Of the 20 most recent actions, 8 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $55 → $62 |
| 6 Nov 2026 | Truist Securities | Maintains | Buy | $37 → $35 |
| 29 Oct 2026 | HC Wainwright & Co. | Assumes | Buy | $55 |
| 7 Oct 2026 | Truist Securities | Maintains | Buy | $39 → $37 |
| 21 Sept 2026 | B of A Securities | Maintains | Buy | $46 → $50 |
| 7 Aug 2026 | JP Morgan | Maintains | Neutral | $31 → $34 |
| 31 July 2026 | Citigroup | Maintains | Buy | $46 → $52 |
| 31 July 2026 | Truist Securities | Maintains | Buy | $41 → $39 |
| 30 July 2026 | HC Wainwright & Co. | Maintains | Buy | $52 → $55 |
| 21 July 2026 | HC Wainwright & Co. | Maintains | Buy | $54 → $52 |
| 7 July 2026 | B of A Securities | Maintains | Buy | $40 → $46 |
| 7 July 2026 | RBC Capital | Maintains | Sector Perform | $28 → $32 |
| 7 July 2026 | Truist Securities | Maintains | Buy | $36 → $41 |
| 15 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 June 2026 | JP Morgan | Maintains | Neutral | — |
| 29 May 2026 | B of A Securities | Maintains | Buy | — |
| 30 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 21 Apr 2026 | B of A Securities | Maintains | Buy | — |
| 20 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Apr 2026 | JP Morgan | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AGIO.
This page is one stock. Monday covers all of them.
AGIO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
AGIO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Agios Pharmaceuticals, Inc. returned +12.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
AGIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 12.3×
- Price / book
- 1.8×
- EV / EBITDA
- —
Cheaper than 10% of US stocks
Cheaper than 48% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 93.3%
- Operating margin
- —
- Net margin
- —
Higher than 97% of US stocks
- Return on equity
- −32.9%
- Return on assets
- −21.4%
- Dividend yield
- —
Higher than 27% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Agios Pharmaceuticals, Inc. has a market value of $1.7B and an enterprise value of $1.1B.
Revenue in the twelve months to 30 June 2026: $98.3M. The latest quarter grew 259.3% year on year.
Net income over the same four quarters: −$411.3M, a −418.2% net margin.
Free cash flow in the twelve months to 30 June 2026: −$390.3M.
Agios Pharmaceuticals, Inc. employs 539 people — $182K of revenue per employee.
Data provided by Twelve Data
AGIO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at AGIO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Agios Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about AGIO
What is the AGIO stock price forecast for 2026-2027?
The 10 Wall Street analysts covering Agios Pharmaceuticals, Inc. have a median 12-month price target of $43, with estimates ranging from $32 to $74. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AGIO stock a buy right now?
Of the 10 analysts covering Agios Pharmaceuticals, Inc., 7 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Agios Pharmaceuticals, Inc. 87 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AGIO?
As at 21 Nov 2026, Agios Pharmaceuticals, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (97 of 100).
Will AGIO stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +55.9% from the last close, and Ticker Nerd's factor model ranks Agios Pharmaceuticals, Inc. 87 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AGIO stock forecast for 2030?
No analyst covering Agios Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AGIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $74 over the next 12 months.
How has AGIO stock performed over the past year?
Agios Pharmaceuticals, Inc. returned +12.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Agios Pharmaceuticals, Inc. do?
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for rare diseases through its expertise in cellular metabolism. The company’s core commercial product is PYRUKYND (mitapivat), an oral pyruvate kinase activator used in hemolytic anemia associated with pyruvate kinase deficiency, with additional development in other hematologic and genetically defined disorders.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for rare diseases through its expertise in cellular metabolism. The company’s core commercial product is PYRUKYND (mitapivat), an oral pyruvate kinase activator used in hemolytic anemia associated with pyruvate kinase deficiency, with additional development in other hematologic and genetically defined disorders. Agios is also advancing investigational therapies for conditions such as thalassemia, sickle cell disease, and phenylketonuria, reflecting its emphasis on rare disease biology and precision medicine. The company operates as a specialized hematology and rare disease developer, combining drug discovery, clinical development, and commercialization capabilities to address unmet medical needs. Agios Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
CEO Mr. Brian M. Goff M.B.A. · 539 employees · United States · https://www.agios.com